Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Abeona Therapeutics Inc’s stock clocked out at $3.26, up 2.19% from its previous closing price of $3.19. In other words, the price has increased by $2.19 from its previous closing price. On the day, 1.21 million shares were traded. ABEO stock price reached its highest trading level at $3.38 during the session, while it also had its lowest trading level at $3.2.
Ratios:
To gain a deeper understanding of ABEO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.15 and its Current Ratio is at 4.15. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.30.
On September 18, 2020, B. Riley FBR started tracking the stock assigning a Buy rating and target price of $5.
On February 10, 2020, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $6.SVB Leerink initiated its Outperform rating on February 10, 2020, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 25 ’24 when O’Malley Brendan M. bought 8,600 shares for $3.24 per share. The transaction valued at 27,864 led to the insider holds 188,718 shares of the business.
Vazzano Joseph Walter bought 5,608 shares of ABEO for $17,609 on Apr 25 ’24. The Chief Financial Officer now owns 233,868 shares after completing the transaction at $3.14 per share. On Feb 06 ’24, another insider, Seshadri Vishwas, who serves as the Chief Executive Officer of the company, bought 20,000 shares for $4.39 each. As a result, the insider paid 87,800 and bolstered with 528,260 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 89177296 and an Enterprise Value of 42351420. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.48 while its Price-to-Book (P/B) ratio in mrq is 5.83. Its current Enterprise Value per Revenue stands at 12.1 whereas that against EBITDA is -0.922.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.62, which has changed by 0.0061728954 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $9.01, while it has fallen to a 52-week low of $2.83. The 50-Day Moving Average of the stock is -55.18%, while the 200-Day Moving Average is calculated to be -35.36%.
Shares Statistics:
It appears that ABEO traded 502.41K shares on average per day over the past three months and 1276590 shares per day over the past ten days. A total of 26.52M shares are outstanding, with a floating share count of 25.91M. Insiders hold about 5.27% of the company’s shares, while institutions hold 52.12% stake in the company. Shares short for ABEO as of 1713139200 were 2061402 with a Short Ratio of 4.10, compared to 1710460800 on 1703738. Therefore, it implies a Short% of Shares Outstanding of 2061402 and a Short% of Float of 7.93.
Earnings Estimates
The dynamic stock of Abeona Therapeutics Inc (ABEO) is currently attracting attention from 3.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$0.51 for the current quarter, with a high estimate of -$0.47 and a low estimate of -$0.6, while EPS last year was -$0.54. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.46 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.92 and -$2.38 for the fiscal current year, implying an average EPS of -$2.14. EPS for the following year is -$1.9, with 3.0 analysts recommending between -$1.38 and -$2.5.
Revenue Estimates
Based on 4 analysts’ estimates, the company’s revenue will be $22.83M in the next fiscal year. The high estimate is $36.7M and the low estimate is $10M.
